1. Home
  2. LBRT vs TGTX Comparison

LBRT vs TGTX Comparison

Compare LBRT & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Energy Inc.

LBRT

Liberty Energy Inc.

HOLD

Current Price

$28.22

Market Cap

4.4B

Sector

Energy

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$28.70

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LBRT
TGTX
Founded
2011
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
4.9B
IPO Year
2017
2008

Fundamental Metrics

Financial Performance
Metric
LBRT
TGTX
Price
$28.22
$28.70
Analyst Decision
Buy
Strong Buy
Analyst Count
12
6
Target Price
$23.00
$50.67
AVG Volume (30 Days)
4.6M
1.5M
Earning Date
04-30-2026
05-29-2026
Dividend Yield
1.29%
N/A
EPS Growth
N/A
1746.67
EPS
0.89
2.77
Revenue
$4,006,116,000.00
$2,785,000.00
Revenue This Year
$0.02
$90.97
Revenue Next Year
$8.06
$45.74
P/E Ratio
$31.26
$10.42
Revenue Growth
N/A
N/A
52 Week Low
$9.50
$25.37
52 Week High
$28.95
$46.48

Technical Indicators

Market Signals
Indicator
LBRT
TGTX
Relative Strength Index (RSI) 67.44 44.34
Support Level $10.82 $27.25
Resistance Level N/A $33.05
Average True Range (ATR) 1.26 1.12
MACD -0.04 -0.02
Stochastic Oscillator 89.24 25.79

Price Performance

Historical Comparison
LBRT
TGTX

About LBRT Liberty Energy Inc.

Liberty Energy Inc is a integrated energy services and technology company focused on providing hydraulic fracturing services and related technologies to onshore oil and natural gas exploration and production (E&P) companies. The Company offers customers with hydraulic fracturing services, together with complementary services including wireline services, proppant delivery solutions, field gas processing and treating, compressed natural gas (CNG) delivery, data analytics, related goods (including sand mine operations), and technologies to facilitate lower emission completions, thereby helping customers reduce emissions profile. The company provides services across USA and Canada.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: